`l_LJt=ENTif:i
`R/:..N i f.'317..U/v'l.t;,, [•1
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Meeting Date: Dec. 20, 2011
`Meeting Notes Date: January 3, 2012
`Author:
`Room: WSJ-340.3.09
`Dial-in:
`
`Executive Summary
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2070.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Discussion & Decisions
`
`Pre-read
`
`I
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2070.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`3.
`
`I
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2070.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Pre-read
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2070.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2070.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Action Plan:
`
`Who ----
`
`..
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2070.006
`Regeneron v. Novartis, IPR2021-00816
`
`